CLASS ACTION UPDATE for LOTZ, CRMD and SAVA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / August 30, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

LOTZ Shareholders Click Here: https://www.zlk.com/pslra-1/carlotz-inc-loss-submission-form?prid=19093&wire=1
CRMD Shareholders Click Here: https://www.zlk.com/pslra-1/cormedix-inc-loss-submission-form?prid=19093&wire=1
SAVA Shareholders Click Here: https://www.zlk.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=19093&wire=1

* ADDITIONAL INFORMATION BELOW *

CarLotz, Inc. (NASDAQ:LOTZ)

LOTZ Lawsuit on behalf of: investors who purchased December 30, 2020 - May 25, 2021
Lead Plaintiff Deadline : September 7, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/carlotz-inc-loss-submission-form?prid=19093&wire=1

According to the filed complaint, during the class period, CarLotz, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) due to a surge in inventory during the second half of fiscal 2020, CarLotz was experiencing a "logjam" resulting in slower processing and higher days to sell; (2) as a result, the Company's gross profit per unit would be negatively impacted; (3) to minimize returns to the corporate vehicle sourcing partner responsible for more than 60% of CarLotz's inventory, the Company was offering aggressive pricing; (4) as a result, CarLotz's gross profit per unit forecast was likely inflated; (5) this Company's corporate vehicle sourcing partner would likely pause consignments to the Company due to market conditions, including increasing wholesale prices; and (6) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

CorMedix Inc. (NASDAQ:CRMD)

CRMD Lawsuit on behalf of: investors who purchased July 8, 2020 - May 13, 2021
Lead Plaintiff Deadline : September 20, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cormedix-inc-loss-submission-form?prid=19093&wire=1

According to the filed complaint, during the class period, CorMedix Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) deficiencies existed with respect to an investigational drug product, DefenCath's, manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the Food and Drug Administration was unlikely to approve the DefenCath new drug application for catheter-related bloodstream infections in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Cassava Sciences, Inc. (NASDAQ:SAVA)

SAVA Lawsuit on behalf of: investors who purchased February 2, 2021 - August 24, 2021
Lead Plaintiff Deadline : October 26, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=19093&wire=1

According to the filed complaint, during the class period, Cassava Sciences, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) the quality and integrity of the scientific data supporting Cassava's claims for simufilam's, a small molecule drug designed to treat Alzheimer's disease, efficacy had been overstated; (b) the scientific data supporting Cassava's claims for simufilam's efficacy were biased; and (c) as a result of the foregoing, Defendants' positive statements during the Class Period about the Company's business metrics and financial prospects and the likelihood of Food and Drug Administration approval were false and misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP